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Objectives: The aim of this study is to conduct an analysis on the regulation and
application of managed entry agreements (MEA) for oncology drugs across different
European countries.
Methods: Literature search and document analysis were performed between
September 2015 and June 2016 to collect information on the regulatory framework and
practice of MEA in Belgium, The Netherlands, Scotland, England and Wales, Sweden,
Italy, Czech Republic and France. An overview of the content and typology of MEA
applied for oncology drugs between 2008 and 2015 was generated based on publically
available sources and contributions by national health authorities. Semi-structured
interviews were conducted with representatives of national health authorities involved
in the management or negotiation of MEA.
Results: The application of MEA differs across countries and across different indications
for the same drug. Financial based agreements are prevailing due to their simplicity
compared to performance-based agreements. Performance-based agreements are
less commonly applied in the European countries except for Italy. In the Netherlands,
application of performance-based agreements was stopped due to their inability to deal
with dynamics in the market, which is highly relevant for oncology drugs.
Conclusions: MEA constitute a common policy tool that public payers in European
countries use to ensure early access to highly priced oncology drugs. In light of strengths
and weaknesses observed for MEA and the expected developments in the oncology
area, the importance of MEA is likely to grow in the future.
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INTRODUCTION
Marketing authorization, price setting and reimbursement of drugs have to maximize accessibility
and affordability of safe and effective drugs. The oncology domain faces important challenges for
market access since the balance between harm and benefits is difficult for aggressive treatments
such as chemotherapy and radiotherapy. While recent targeted therapies more selectively
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strike disease targets, benefits are often hard to measure in a
clinically relevant way within the limited timeframes of clinical
studies. Over the last decade, health systems were increasingly
burdened with fast growing expenditures on oncology drugs,
with a total expenditure in Europe from 7.6 billion in 2005 to 19.1
billion in 2014 (Jönsson et al., 2016). Uncertain benefit-risk ratios
put the high prices for oncology drugs under debate (Garattini
and Bertele, 2002; Fojo and Grady, 2009; Abboud et al., 2013;
Pauwels et al., 2014; Fojo and Lo, 2016; Gozzo et al., 2016).
The European Commission (EC) can grant marketing
authorization (MA) after the European Medicines Agency
(EMA) approves the quality, safety and efficacy of the
drug, requiring applicants to provide solid grounds on these
requirements1. When the benefit of immediate availability
outweighs the risk of incomplete data, conditional marketing
authorization can however be granted in the interest of public
health. A pilot project on adaptive pathways explored the
implications of progressive patient access in parallel with the
development of the drug, applied within the current regulatory
framework for marketing authorization in areas of high medical
need. Through adaptive pathways, conditional approval can be
granted to a restricted patient group based on early data, while
its use will enable real-life evidence generation that can be
considered to broaden the approved patient population. Of the 62
proposals for the adaptive pathways pilot project, anti-neoplastic
agents were the leading group of therapeutic agents (33%)
(Eichler et al., 2015).
Trends toward early marketing authorization have potential
benefits for patients, but also limit data availability for pricing
and reimbursement decisions. Each European Member State
takes into account its own regulations and economics for price
setting and reimbursement, leading to heterogeneity in pricing,
reimbursement and access to oncology drugs across Europe
(Pauwels et al., 2014; Vogler et al., 2015)2. Managed entry
agreements (MEA) are contractual agreements between the
marketing authorization holder (MAH) and health care payers
that are introduced when decisive “yes” or “no” conclusions on
price and reimbursement could not be made due to uncertainties
about the clinical evidence and/or financial impact of the drug
(Carlson et al., 2009). Several countries apply MEA and different
terminology and typology is identified, but the common factor
is that MEA allow market access of drugs by sharing the
cost of uncertainty between the payer and the MAH. MEA
are an attractive mechanism for market access of oncology
drugs (Ferrario and Kanavos, 2015; van de Vooren et al.,
2015; Executive Insight Health Care Consultants, 2016). The
aim of this study is to conduct a comparative analysis of
the regulation and application of MEA for oncology drugs
between European countries. Given current evolutions that
will further complicate market access decision for oncology
drugs, the experiences from the past will be investigated to
draw lessons for the future application of MEA for oncology
drugs.
1European Medicines Agency. 2015. 18-2-2017. Ref Type: Online Source.
2Wilkings. Patient access for oncology drugs. 2012. Ref Type: Internet
Communication.
METHODS
Literature search and document analysis was performed between
September 2015 and June 2016 to collect information on the
application of MEA in Belgium, the Netherlands, Scotland,
England and Wales, Sweden, Italy, Czech Republic and France.
Selection of countries was based on geographical distribution and
variety in financing of health care system (compulsory health
insurance vs. general taxation) and organization of health care
system (National Health Service vs. insurance based). Literature
was searched in PubMed and EMBASE based on but not limited
to the following search terms: managed entry agreement(s), risk-
sharing agreement(s), patient access scheme(s), performance-
based reimbursement, coverage with evidence, price-volume
agreement, discount, conditional reimbursement. The websites
of national health authorities and organization involved in
research related to health policy such as International Society
for Pharmaco-economics and Outcomes Research (ISPOR)
were consulted. Information was further refined through semi-
structured interviews with the relevant authorities involved
in the set-up and negotiation on MEA, including selected
members of the Pharmaceutical Pricing and Reimbursement
Information (PPRI) network. The interviews were conducted
by telephone and are audio-recorded, ad verbatim transcribed
and analyzed using the grounded theory approach. A country-
specific summary on the results was presented to the national
health authorities for validation. For each country, an overview of
MEA applied at national level between 2008 and 2015 (including
MEA set up since 2008 but expired during this period), for drugs
intended to treat solid tumors or hematological malignancies,
was generated. Agreements focusing onmeasures for appropriate
use only, were not included. A reporting template was designed
to include the drug name, substance name of the MAH, ATC
code, indication, start-date of MEA, dates of prolongation of
MEA and predicted end-date of MEA. All MEA were assigned
to the typology described by Morel et al. (2013). If information
could not be retrieved from publically available sources or
was incomplete, it was requested from the national competent
authorities. In case that information could not be disclosed due
to confidentiality, descriptive numbers on the typology of MEA
applied in the country of interest were requested. Descriptive
analysis on the dataset was performed in Excel.
RESULTS
A country specific overview about the institutional and legal
framework valid forMEA, as well as a comprehensive overview of
the content of MEA for which data were retrieved, can be found
in Supplementary Information.
For Belgium, Scotland, Sweden, England, Wales, and Italy,
information about 164 specific MEA was collected. Information
on MEA applied in Belgium, Sweden and Italy was obtained
from health authorities, while publically available sources were
available for England, Wales and Scotland. The 164 MEA
identified in this study, involve 58 individual drugs. Majority
of identified MEA was applied by Italy (63/164), followed by
Scotland (43/164), England (28/164), and Belgium (28/164).
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For the Czech Republic, 19 MEA are applied for oncology
drugs. Descriptive information was obtained from the Insurance
Funds Union. In France, theMinistry of Social Affairs andHealth
indicated that all information about MEA is strictly confidential.
Literature indicated the existence of two MEA for oncology
drugs3. In the Netherlands, the application of MEA was under
transition at the time of this study and by 2016, an agreement was
concluded for an oncology drug (nivolumab) for the first time
since the reform.
Characteristics of the Drugs
Considering all MEA for which information about drug
characteristics was retrieved (N =164), a third of MEA (47/164)
applies to Orphan Medicinal Products (OMP). Hematology is
the leading disease area subjected to MEA (74/164). Detailed
information on the indications of the drugs that are subjected to
these MEA can be found in Supplementary Information.
Forty out of 164 MEA involve a drug that is subjected to a
MEA in two or more of the countries considered, but the content
of the schemes varied across countries.
Bevacizumab was the drug with the highest number of MEA,
i.e., 10 MEA were applied across three different countries and
six different indications. Italy applied a MEA for five different
indications of bevacizumab and the type of scheme differs
between different indications. This is illustrated by a financial
based agreement for first line treatment of colorectal cancer,
while a performance-based agreement is applied for second line
treatment of this disease. Also in Belgium, the agreement can be
differentiated across indications.
For only two drugs, enzalutamide (Xtandi R©) and
aberitaterone acetate (Zytiga R©), MEA were applied in all
six countries considered for data collection. Both drugs are used
in prostate cancer and also in this case, Belgium and Italy distinct
the MEA based on first and second line indication. For Xtandi R©,
all countries applied financial based agreements. For Zytiga R©, a
performance-based agreement was applied in Italy, while other
countries applied financial-based agreements.
For Czech Republic and France, no complete information on
characteristics of diseases covered by MEA could be obtained.
Characteristics of the Schemes
For Italy, England, Wales, Scotland and Sweden, specific
information on the content of schemes was retrieved (N =
136) (Supplementary Information). Financial agreements were
prevailing, with only one third of schemes (40/136) having a
performance-based component. Except for three performance-
based agreements applied in England, Wales and Scotland, all
these MEA with a performance-based components were applied
in Italy. As performance-based agreements are rare or inexistent
in the majority of countries included in this study, we cannot link
the typology of the schemes to the typology of the drugs that are
involved.
In the Netherlands, performance-based agreements were
applied in the past but the system is now under reform to
only apply financial agreements. In France, a performance-based
3French Healthcare products pricing committee. 2015/2015 Annual Report. 2016.
contract was signed for Imnovid R© in 2014, indicated to treat
multiple myeloma3.
Transparency of the Agreements
For Belgium and France, the content of MEA is strictly
confidential for all parties who are not involved in the
negotiation.
In the Czech Republic, the contents of MEA are confidentially
negotiated between MAH and the Insurance Funds Union, who
is responsible for reimbursement. The details of the scheme are
not disclosed to the State Institute of Drug Control, who is
responsible for price setting of drugs.
Information on medicines subject to a MEA is public
information in Italy, England, Wales and Scotland and Sweden.
Confidentiality of financial details is however the cornerstone of
the application of MEA irrespective of the country where the
MEA is applied. The Pharmaceutical Price Regulation Scheme
(PPRS) that is valid in United Kingdom (UK) states that all MEA
should be transparent, with an exception when theMinisters have
agreed that the details of the discount can remain commercial-
in-confidence. When a medicine subject to an agreement is used
as a comparator for the appraisal of another treatment, relevant
details of the MEA need to be available to relevant consultees and
commentators.
Financial-Based Agreements
Financial agreements in the form of discounts are the prevailing
form of MEA applied for oncology drugs (Figure 1).
In England, Wales, and Scotland, the PPRS specifies that
MEA should be clinically robust, clinically plausible, appropriate,
and operationally manageable for the National Health Service
(NHS) without unduly complex monitoring, disproportionate
additional costs and bureaucracy. Therefore, simple discount
schemes take the lead, although the option for complex schemes
remains available. Complex schemes include all other types of
MEA such as rebates (which involve a separate transaction
whereas a discount is applied directly to original invoices), stock
supplied at zero cost (free stock), dose capping (agreement
of manufacturers and payers on a pre-determined level of
consumption, with manufacturers covering any additional costs
incurred beyond this limit), and outcome-based schemes called
response schemes. Scotland considers whether a MEA applied by
England is feasible in Scotland, given infrastructure differences
between England and Scotland which can influence the feasibility
of a particular scheme, for example different IT capability.
Furthermore, differences in supply chain of medicines can have
an impact on the feasibility, illustrated by the involvement of
community pharmacies in the supply of specialty medicines in
Scotland, which is not the case in England.
Also in Czech Republic, the majority ofMEA (13/19) involve a
simple confidential discount, referred as price declaration. MEA
are applied to meet the willingness to pay (WTP), which is
considered to be three times the GDP of the country.
For Belgium, no details on the characteristics of the MEA are
available due to confidentially. The annual report of the National
Institute of Health and Disability Insurance (NIHDI) however
states that, in the majority of MEA the health insurance will
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FIGURE 1 | Typology of MEA applied for oncology drugs across European countries (N = 164).
initially bear the costs of drugs and theMAHwill rebate an agreed
amount of money to the NIHDI after a specified period of time.
The rebate can be determined in function of the turnover of the
MAH or the rebate can be based on the performance of the drug4.
In Sweden, all MEA for oncology drugs involve a patient
utilization cap. Therefore, a national registry funded by the
Government and set up by the National Board of Health and
Welfare delivers data on volume and use of pharmaceuticals,
based on the input of pharmacists. Registries are also available
at the county councils, although its use for MEA is complicated
due to heterogeneity across the councils and therefore, patient
utilization caps are declined for in-patient medicines in the
system that is in place in 2016.
In France, a study conducted by European Medicines
Information Network (EMINet) reported that a price-volume
contract is applied for an oncology drug between 2010 and 2015
with the aim to control budget, but its name is not disclosed due
to confidentiality (Espin et al., 2011).
In the Netherlands, financial agreements have been applied
for extramural care since 2012 in case of an unfavorable cost-
benefit ratio or when the budget impact is more than average
and the situation of the market can not address the high price or
high expenditures, for example due to a lack of competitor drugs.
In 2015, the application of financial agreements was extended
to inpatient drugs as well. During a horizon scan, the cost and
volume consequences of products that are expected to enter the
market in the next year are evaluated. When the costs are too
high and it is unlikely that these can be addressed by the market
4RIZIV/INAMI. M.O.R.S.E semesterieel rapport 2014.(2). 2012. 20-1-2013. Ref
Type: Online Source.
situation or negotiations held under the responsibility of the
hospitals themselves, the drugs are “locked” from entering the
market until negotiation of an agreement. Financial agreements
imply that the company will rebate a certain amount to the
Health Insurers, over a specified period of time. The rebate can be
organized in different ways, such as price/volume agreements or
discounts. The rebates are confidential and organized by a trusted
third party, who is responsible for administrative aspects of the
rebate but not involved in the negotiation. In April 2015, mutual
negotiations between the Netherlands and Belgium, extended
by Luxembourg in September 2015 and by Austria in June
2016, were announced but experiences were not available at the
moment of publication5,6.
Performance-Based Agreements
In Italy, a majority of MEA are performance-based to decide
on a refund for non-responders (35/63) at patient-individual
level. Six percent have both performance-based as well as
financially based aspects (4/63). Standard monitoring registries
are applied independently from MEA, and can be employed to
monitor patient response in the context of performance-based
agreements. These registries are web-based tools organized by the
Italian Medicines Agency (AIFA) to share clinical information
and safety data between regulators, clinicians and pharmacists.
Registries are based on IT facilities that receive financial support
from pharmaceutical companies.
5Ministre des Affaires sociales et de la Santé publique. The Grand Duchy of
Luxemburg Joins Belgium-Netherlands Initiative on Orphan Drugs. 24-9-2015.
Ref Type: Online Source.
6Bundesministerium fur gezundheit. Österreich tritt Benelux-Kooperation für
Arzneimittelpolitik bei. 17-6-2016. Ref Type: Online Source.
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Also in the Netherlands, several schemes are set-up since 2008,
in the context of the policy measure for expensive medicines and
OMP, but the Health Care Institute (Zorginstituut) experienced
that data gathered over the last years only poorly address the
uncertainties that were left at the moment that reimbursement
was filed in the Netherlands. The quality of the data collected
within such schemes depended on the engagement of clinicians,
who have little incentive to devote resources and time to data
collection. The validity of the data collected within such schemes
was often affected by scientific evolutions, new product launches
in the market and changing clinical practice that result thereof,
especially in dynamic domains such as oncology. Therefore,
appropriate use is preferred instead of follow-up research.
Examples on measures for appropriate use involve designation
of expertise centers and the definition of start and stop criteria
for use of the medicine. In 2016, the Health Care Institute
(Zorginstituut) was evaluating the feasibility and usefulness of
a re-evaluation for each dossier and the manufacturers will be
informed about the decision.
Duration of the Agreements
In England andWales, the lifetime of the relevant guidance from
the National Institute of Health and Care Excellence (NICE)
determines the duration of the MEA, but the exact agreement
needs to be clear and conditions on MEA’s termination need to
be specified. In case of new indications or changes in the scheme
type, a new MEA submission is required.
In Scotland, MEA are by rule applied for 5 years, unless there
is a price decrease. After 5 years, the company can indicate to
continue or stop the MEA however the product should continue
to be available at the price agreed within the MEA or a lower list
price.
In Italy, decision on price setting and reimbursement are
usually re-evaluated after 24 months, but the duration of MEA
can be adjusted on a case-by-case basis. MEA can be extended
at time of re-evaluation or the content can change, illustrated
by Adcetris R© where a performance-based scheme was switched
to a financial agreement in July 2014 for both Hodgkin and
Non-Hodgkin lymphoma.
In the Netherlands, the duration of a financial agreement
is dependent on the product and on future products that
are expected to enter the market. It is continuously evaluated
whether the price cannot be subjected to market forces
such as competition. The dynamics in the oncology domain,
combination of treatments and multiple indications for certain
drugs make the oncology domain complex as for some
indications competition is possible and for others not.
Also in the Czech Republic, the market is continuously
evaluated. The duration of a MEA is usually 3 years and
afterwards, new information gained from registries, experience in
other countries or published studies about effectiveness or safety
will be considered during re-evaluation.
In Belgium, the duration of a MEA is case dependent and
varies between 2 and 3 years. The majority of MEA for which the
end date has passed, were extended. Furthermore, MEA continue
despite the introduction of competitor treatments, which are also
subjected to a MEA at their turn (Supplementary Information).
DISCUSSION
To the best of the authors’ knowledge, this study is the first
to provide a comprehensive overview of the current practice of
MEA applied for oncology drugs (including drugs that intend to
treat solid tumors as well as hematological malignancies) in a set
of European countries.
The application of MEA is heterogeneous across countries
(Ferrario and Kanavos, 2015). First, the variety in health care
systems and economic aﬄuence of individual European countries
leads to heterogeneous price setting and reimbursement practices
across different countries (Garattini and Bertele, 2002; Edlin
et al., 2014). Second, contextual differences with regard to data
collection infrastructure and supply chain of specialty medicines
influence the feasibility to apply the different types of MEA
in a certain country. Contextual factors can differ between
countries but also within countries dependent on regions (i.e.,
Sweden) or territories (UK). Despite the fact that the application
of MEA is heterogenous across European countries, MEA
contribute to accessibility at the level of individual countries by
allowing patient access to drugs that would not be reimbursed
otherwise.
Our study shows that as of 2016, financial based agreements
in the form of direct or indirect price reductions were the
most common form of MEA applied for oncology drugs in
the countries included in this study. The same observation
is reported by studies that consider MEA across all disease
domains (Vogler et al., 2012; Morel et al., 2013; Executive
Insight Health Care Consultants, 2016). Studies conducted before
2015, however, show that performance-based agreements are
commonly applied in Sweden and the Netherlands (Morel et al.,
2013; Ferrario and Kanavos, 2015; van de Vooren et al., 2015).
As payers were struggling to define and measure the outcome,
they increasingly refrained from this type of MEA. The poor
relationship between short term surrogate outcomes and hard
endpoints is, in general, a major limitation of performance-based
schemes in which reimbursement is coupled to performance
of the drug in either a patient population (coverage with
evidence development) or at patient individual level (Ferrario
and Kanavos, 2015). Furthermore, the value of information will
typically be lower than the cost of data collection (Edlin et al.,
2014).
Rapidly evolving markets, such as present for oncology,
require a dynamic approach for the value of drugs where
mechanisms for market access can adapt to new competitors
and comparators are introduced. Data collection at the level
of a patient group, such as applied by coverage with evidence
development, is a rigid system in which conditions for data
collection are fixed over longer periods of time. Due to
limited flexibility to adapt data requirements in function of
new evolutions in the market, the relevance of data collected
is often disputed. Nevertheless, a study conducted by Toumi
et al. showed that coverage with evidence agreements can
provide answers about uncertainties in real world effectiveness
by using patient relevant outcomes (Toumi et al., 2017).
Although performance-based agreements at patient individual
level can allow more flexibility to adapt to changes in the
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market over time, rigid outcomes based on surrogate end-points,
are applied in pay for performance agreements (Toumi et al.,
2017).
Experience with performance-based schemes on individual
patient level has meanwhile been made for more than 10
years in Italy. Payback by the MAH of treatment for non-
responding patients faced challenges due to inefficiency of
health care centers who have to collect the data and claim
payback4. Additionally, interruptions of treatment due to reasons
other than what is agreed in the context of the scheme can
lead to dispute about the payback of treatments (Navarria
et al., 2015). Success fees, also described as outcomes guarantee
in the literature (Morel et al., 2013), apply a retrospective
payment by the payer for patients who have benefited from
a treatment4. In our study, outcome guarantees applied for
oncology drugs were only observed in one single case in Scotland.
Outcomes guarantees linked to high thresholds for response
can increases the likelihood that the drug will be paid by the
MAH, limiting the costs for the public payer, especially for high
cost oncology drugs. When the agreement expires, the content
of the agreement will be considered during the negotiation
fur future reimbursement. The incentive to set high thresholds
for response can limit the use of drugs for certain types of
patients, and despite the benefits for the public health care
budget, patient advocates can perceive this as a threat. On the
other hand, drugs are supplied for free within the context of an
outcomes guarantee or similar schemes that apply conditional
treatment continuation, and therefore there is the risk that they
are used beyond the most beneficial patient population. Defining
objective, clinically meaningful outcomes that are measurable
within restricted timeframes and available IT infrastructure will
be challenging.
Financial agreements offer financial security for payers at
a lower cost of data collection, however, the administrative
workload can still place a burden on health care systems.
Although the hurdles in price setting and reimbursement are
clearly composed by clinical uncertainties (relative efficacy
or effectiveness), financial uncertainties (budget impact) or a
combination of both (cost-effectiveness), our study showed that
simple discount schemes take the lead, despite the fact that this
type of agreement shows the least opportunities for sharing the
risk (i.e., cost of uncertainties) between the payer and the MAH.
External reference price setting (i.e., price setting based on the
price in other countries) in Europe is one of the economic
drivers behind the application of MEA. MEA allow MAHs to
differentiate prices between countries in a confidential manner,
impeding the effect of a price decrease in reference countries on
the price of other countries (Leopold et al., 2012). MEA and other
confidential price reductions flaw the system of external reference
price setting as the list price does not reflect the real price covered
by the payers. Furthermore, focus on financial impact instead
of drug value can urge MAHs to anticipate price decreases and
consequently, payers will distrust the price proposed by MAHs
(Vogler et al., 2012; Executive Insight Health Care Consultants,
2016; Pauwels, 2016).
Oncology drugs are characterized bymultiple indications with
more than 50% of major cancer medicines marketed for multiple
indications in 2014 (Mestre-Ferrandiz et al., 2015)7. Even within
a certain type of cancer, the benefits of the drug will differ
dependending on the stage of the disease and the risks that
will be considered acceptable will be higher for advanced stage
disease compared to first line settings. This study showed that
in a limited number of countries, e.g., Belgium and Italy, MEA
allow to distinct the price across indications, despite a single
list price that is valid for all indications for which the drug is
marketed. In UK, the launch of new indications for a product
subjected to aMEA requires that theMEA is reconsidered, taking
into account the full set of indication. In addition to benefit that
are indication specific, it is unlikely that the uncertainties can
be generalized across different indications for a given drugs and
therefore, MEA can only be based on evidence when specific
indications are considered. Due to the dynamics of the oncology
market, fixed contract durations can only be applied when the
launch of a specific drug in new indications, or the launch of
other drugs in the same indication, is taken into account based
on horizon scanning. While the application of indication specific
MEA can provide incentives to the pharmaceutical industry to
broaden indication of oncology drugs, even when the benefits
are lower compared to the initial indication, applying a single
MEA to different indications for the same product can discourage
industry to apply for reimbursement in new indications as
this can induce additional discounts or rebates within a MEA
(Pauwels et al., 2016). Although the latter case in theory can limit
the reimbursement of the product to those indications where
the highest value is perceived, it can jeopardize accessibility to
oncology drugs for patients in high need or it can induce off-label
use of the product with unexpected costs for public health care
systems as a consequence.
A large number of the identified MEA was extended after
expiration. On the one hand this can be due to the lack of
answers toward the uncertainties that were formulated. On the
other hand, MEA for different drugs that intent to treat the same
indication were observed within some countries during this study
and are likely to maintain the existence of a contract over time.
When a drug for which reimbursement is applied, is compared
to alternatives with a confidential price, the new application is
likely to result in a MEA as well. Due to extensive prolongation of
MEA, the MEA can persist through the lifecycle of the product,
and the question on how to deal with generic competition for
products that have a confidential price due to a MEA will arrive
soon.
This study suffers from several limitations. No complete
data set could be obtained due to confidentiality in some
countries. Unavailability of data was partially compensated by
a descriptive overview. Furthermore, caution is needed with
regard to the comparability of the application and regulatory
framework for MEA in different countries that each have their
own legislation with regard to health policy. This provided
however a broad range of experiences from which countries can
learn.
7IMS Institute for healthcare informatics. Developments in Cancer Treatments,
Market dynamics, Patient Access and Value. 2015. 29-2-2016. Ref Type: Online
Source.
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CONCLUSIONS
MEA appear to be a common policy instrument for public
payer given the complexities of price setting and reimbursement
of drugs. Given the pressure on authorities to ensure earlier
market access of drugs, as well as new challenges due to
new therapeutic mechanisms such as immune oncology,
MEA are likely to stay in the future oncology drug market.
The experience from the past however shows that in order
to exploit the benefits of MEA related to accessibility
for patients, affordability for society and profitability by
pharmaceutical companies, the dynamics of the oncology
market need to be taken into account when MEA are set
up.
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